Several authoritative organizations have issued new guidelines about hormone therapy (HT)—an area that has led to confusion and conflicting guidelines for the past decade. A coalition of 15 medical groups, including the North American Menopause Society, issued a statement declaring that HT is acceptable for short-term use in healthy women with marked menopausal symptoms up to age 59 or within 10 years of menopause. Short-term use in women of that age does not increase the risk for heart attack and stroke, and does relieve symptoms of menopause. However, the U.S. Preventive Services Task Force recommends against long-term use of HT for the purpose of preventing chronic medical conditions, as contrasted with the purpose of treating menopausal symptoms.
To continue reading this article, you must login
Subscribe to Harvard Health Online for immediate access to health news and information from Harvard Medical School.